Form 4 for IDXX Idexx Laboratories
Accepted 2022-02-18 00:00:00 ET · period of report 2022-02-17 · accession 0001567619-22-005125 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-18 | 2022-02-17 | IDXX | Underberg Sharon E. | EVP, GC, Corp. Sec | M - OptEx | $206.94 | +483 | 2,987 | +19% | +$100.0K |
| D | 2022-02-18 | 2022-02-17 | IDXX | Underberg Sharon E. | EVP, GC, Corp. Sec | M - OptEx | — | -483 | 966 | -33% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-02-17 | M | A | 483 | $206.94 | 2,986.99 | D | — | — | |
| 2 | Derivative | Incentive Stock Option (right-to-buy) | 2022-02-17 | M | D | 483 | — | 966 | D | $206.94 · — to 2029-02-13 | 483 Common Stock | (F2) Not applicable. (F1) Grant of option to buy shares of Issuer common stock that becomes exercisable in five annual installments beginning February 14, 2020. |